A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers

Abroad (travel likely)RecruitingPHASE2

Conditions

Carcinoma, Hepatocellular · Gastric Adenocarcinoma · GastroEsophageal Cancer · Oesophageal Cancer · Non-small Cell Lung Cancer · Head and Neck Squamous Cell Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Department of Hematology-Oncology, National University Hospita, Singapore, Singapore
Contact: Study coordinator (Wei Peng Yong) · Wei_Peng_YONG@nuhs.edu.sg · +65 6908 2222

Study leads

Wei Peng Yong
Principal Investigator
National University Hospital, Singapore

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Phase 1 Study of the Safety and Tolerability of CTX-10726

Gastroesophageal Cancer (GC) · Hepatocellular Carcinoma (HCC) · Endometrial Cancer

Abroad (travel likely)RecruitingPHASE1

Boston, United States · Omaha, United States

18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors

Clear Cell Renal Cell Cancer (ccRCC) · Urothelial Carcinoma (UC) · Colorectal Cancer

Abroad (travel likely)Recruiting

Beijing, China

Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors

Hepatocarcinoma · Lung Cancer · Melanoma

Abroad (travel likely)RecruitingPHASE2, PHASE3

Guanzhou, China

Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies

Solid Tumor, Adult · Triple Negative Breast Cancer · Colorectal Cancer

Abroad (travel likely)RecruitingPHASE1

Scottsdale, United States · La Jolla, United States